TD Cowen analyst Michael Nedelcovych maintained a Buy rating on Molecular Partners AG (MLLCF – Research Report) on March 7 and set a price target of CHF15.00.
Michael Nedelcovych has given his Buy rating due to a combination of factors including Molecular Partners AG’s strong financial position and promising pipeline developments. The company ended 2024 with a solid cash reserve of CHF 149 million, which is expected to support operations until 2027. This financial stability is complemented by a better-than-expected revenue performance and lower expenses in 2024, indicating efficient management of resources.
Furthermore, Molecular Partners AG is advancing its innovative pipeline, particularly with the upcoming data readouts for its DLL3 RadioDARPin program, which is poised to enter clinical trials. The collaboration with Orano Med on the MP0712 candidate targeting DLL3, a protein associated with small cell lung cancer, highlights the company’s strategic focus on high-potential therapeutic areas. These factors collectively suggest a positive outlook for the company’s growth and investor interest, justifying the Buy rating.
Questions or Comments about the article? Write to editor@tipranks.com